

11<sup>th</sup> June 2014

The Manager, Listings
Australian Securities Exchange Limited
Company Announcements Office

Dear Sir

re: OAKTON LIMITED

Appendix 3B - amended

The Appendix 3B lodged with the ASX on 11<sup>th</sup> June 2014 and released at 10:06am disclosed obsolete information in Annexure 1, Part 1 (pages 11 to 12).

Attached is the amended Appendix 3B in which Annexure 1, Part 1 discloses correct information. Please note that the information contained in pages 1 to 10 is not affected by this correction.

Yours faithfully

**Michael Miers** 

Company Secretary
Oakton Limited

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name	Name of entity		
OAK	OAKTON LIMITED		
ABN			
50 00	07 028 711		
We (the entity) give ASX the following information.			
_	t 1 - All issues ust complete the relevant sections (attach si	heets if there is not enough space).	
1	*Class of *securities issued or to be issued	Performance Rights	
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	678,717	
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Refer below	

For the FY14 grant, the Performance Rights will be performance tested over a period of three years from 1 July 2013 to 30 June 2016. As such, Performance Rights will not vest until 30 June 2016.

The FY14 grant will be performance tested 408,117 based on Relative Total Shareholder Return (Relative TSR) performance, and 270,600 based on Absolute Diluted Earnings per Share (EPS) performance.

1/1/2003 Appendix 3B Page 1

<sup>+</sup> See chapter 19 for defined terms.

Up to 100% of the allocated Performance Rights may vest, subject to the achievement of the Performance Hurdles and service Vesting Condition as set out below.

Any Performance Rights that do not vest and become exercisable, will automatically lapse.

#### **Relative TSR**

TSR measures the return received by shareholders from holding shares in a company over a particular period. TSR is calculated by taking into account the growth in a company's share price over the period as well as the dividends received during that period. The formula for calculating TSR is shown below:

A volume weighted average share price (VWAP) will be used to determine Share Price at Test Date and Share Price at Start Date.

The VWAP for the Share Price at Start Date will be based on the VWAP over the 10 days prior to the Date of Grant and the VWAP for the Share Price at the Test Date will be based on the VWAP over the 10 days after the two year anniversary of the Date of Grant.

The TSR will be measured against the S&P/ASX300 (excluding financial services, infrastructure funds and mining/property/manufacturing companies).

No Performance Rights will vest unless the percentile ranking of the Company's TSR for the relevant performance year period as against the Comparative TSRs for the relevant performance year period is at or above the 50th percentile.

The vesting schedule is as follows:

Relative TSR performance	Performance Vesting Outcomes
Less than 50 <sup>th</sup> percentile	0% vesting
At the 50 <sup>th</sup> percentile	50% vesting
Between 50 <sup>th</sup> and 75 <sup>th</sup> percentile	Between 50% and 100% vesting, calculated on a linear basis.
At or above 75 <sup>th</sup> percentile	100% vesting

#### **Absolute EPS**

Oakton's EPS performance will be measured across the relevant performance period. Absolute EPS measures the portion of a company's profit allocated to each outstanding ordinary share and serves as an indicator of a company's profitability. It is prescribed by the Accounting Standards and set out in the financial statements.

Appendix 3B Page 2 1/1/2003

<sup>+</sup> See chapter 19 for defined terms.

No Performance Rights will vest unless the performance of Oakton's EPS is equal to or more than the threshold earnings per share price growth, as measured across the relevant performance period.

The vesting schedule is as follows:

Compound annual EPS growth	Performance Vesting Outcomes
Less than 10% pa	0% vesting
At 10% pa	50% vesting
More than 10% pa but less than 15% pa	Between 50% and 100% vesting, calculated on a linear basis.
At 15% pa or greater	100% vesting

1/1/2003 Appendix 3B Page 3

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	NIL
6	D (4)	
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Issued per terms agreed by the Shareholders at the AGM held on 02 October 2013
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?	No
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	
6с	Number of *securities issued without security holder approval under rule 7.1	
6d	Number of *securities issued with security holder approval under rule 7.1A	

Appendix 3B Page 4 1/1/2003

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)		
ć £	NT	Γ	
6f	Number of *securities issued under an exception in rule 7.2		
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.		
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements		
		Г	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements		
		<b>-</b>	
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	11 June 2014	
	Cross reference: item 33 of Appendix 3B.		
		Number	+Class
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	89,990,235	ORD(ASX code:OKN)

<sup>+</sup> See chapter 19 for defined terms.

9 Number and +class of all +securities not quoted on ASX (including the +securities in section

Number	<sup>+</sup> Class	
722,500	Options with various expiry dates	
	(ASX code : OKNAI)	
2,012,807	Performance Rights	
	(ASX code : OKNAK)	

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

The rights and options do not rank for dividend however, any shares arising from the exercise of rights and options will rank equally with all other ordinary shares from the date of their allotment save in respect of any dividends, rights or other distributions for which the record date falls before the date of the exercise of the rights and options


Part	2 - Pro rata issue
11	Is security holder approval required?
12	Is the issue renounceable or non-renounceable?
13	Ratio in which the *securities will be offered
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates
15	+Record date to determine entitlements
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
17	Policy for deciding entitlements in relation to fractions
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.
	Cross reference: rule 1.1.

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
/32	How do security holders dispose of	

<sup>+</sup> See chapter 19 for defined terms.



Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Enti	ties that have ticked box 3	4(b)
38	Number of *securities for which *quotation is sought	
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
41	Reason for request for quotation now  Example: In the case of restricted securities end of restriction period  (if issued upon conversion of another *security, clearly identify	
	that other +security)	
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number +Class

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before <sup>†</sup>quotation of the <sup>†</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Michael Miers Company Secretary

11 June 2014

== == == ==

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Insert number of fully paid <sup>+</sup> ordinary securities on issue 12 months before the <sup>+</sup> issue date or date of agreement to issue	89,777,735
Add the following:	
Number of fully paid *ordinary securities issued in that 12 month period under an exception in rule 7.2	50,000
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval	
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period	
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	-
"A"	89,827,735

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
<b>Multiply</b> "A" by 0.15	13,474,160
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used	
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	162,500
• Under an exception in rule 7.2	
Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	162,500
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1  "A" x 0.15	
Note: number must be same as shown in Step 2	13,474,160
Subtract "C"	162,500
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	13,311,660
	[Note: this is the remaining placement capacity under rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 12 04/03/2013

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
ure from which the placement	
0.10	
Note: this value cannot be changed	
of placement capacity under rule	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	
Note: number must be same as shown in Step 2	
Subtract "E"	
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.10] – "E"	
	Note: this is the remaining placement capacity under rule 7.1A

Appendix 3B Page 14 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.